Steep new US tariffs on pharmaceuticals and cuts to the country's Food and Drug Administration and National Institutes of Health are creating fresh challenges for biotech globally — but also surprising opportunities for Australia. Industry leaders say targeted investments in R&D, streamlined visa processes for international scientific talent, and smart trade negotiations could put Australia in a position to thrive amid the upheaval. Read the full story by Bronwen Clune 👉https://lnkd.in/gptN6ivr
CEO @ Proto Axiom | Life Sciences Investor, Company Builder
6dSame headline is getting recycled a bit. Hopefully this leads to some action.